RI therapy

[BP2G-05] Monitoring of Ra-223 therapy by FDG-PET/MRI and bone SPECT in CRPC patients with bone metastases

Shigeyasu Sugawara^1,2, Daiki Kayano^1,4, Shiro Ishii², Kei Ishibashi³, Yoshiyuki Kojima³, Hiroshi Ito², Noboru Oriuchi¹ (1.Department of Radionuclide Therapy, Fukushima Medical University Hospital, 2.Department of Radiology and Nuclear Medicine, Fukushima Medical University, 3.Department of Urology, Fukushima Medical University, 4.Department of Nuclear Medicine, Kanazawa University Hospital)